key: cord-0926375-gqkkp0i0 authors: Zhang, Yue-Miao; Liu, Xing-Zi; Lin, Miao-Miao; Zan, Jin-Can; Hu, Yi-Tong; Wang, Xiang-Qiu; Wu, Wen-Qi; Zhou, Tai-Cheng; Lv, Ji-Cheng; Zhang, Hong; Yang, Li; Zhang, Zi-Jie title: Immunosuppression impaired the immunogenicity of inactivated SARS-CoV-2 vaccine in non-dialysis kidney disease patients date: 2022-05-09 journal: J Infect DOI: 10.1016/j.jinf.2022.05.003 sha: f275b784b5722ce68633c946640a58a4b0a27bc8 doc_id: 926375 cord_uid: gqkkp0i0 nan Previous studies focused on exploring immune responses to COVID-19 vaccine in patients on dialysis or receiving kidney transplant (2, 3) . Three recent studies reported the humoral response to mRNA SARS-CoV-2 vaccines in patients with CKD (4-6), yet no serial data available for inactivated SARS-CoV-2 vaccines. We conducted a pilot, prospective study to survey the safety and humoral response to inactivated SARS-CoV-2 vaccine in CKD patients receiving a 2-dose immunization of inactivated SARS-CoV-2 vaccine ( Figure. Table 1 . All participants received a 2-dose immunization (3-5 weeks between two doses) of inactivated SARS-CoV-2 vaccine (SinoVac or Sinopharm). We collected serum samples 20-33 days after the second dose of vaccination. To assess the humoral response to inactivated SARS-CoV-2 vaccines, we measured neutralizing antibody (competitive inhibition method), SARS-CoV-2-specific IgG and IgM using chemiluminescence immunoassay (MCLIA, Bioscience Co., Tianjin, China). We also recruited 31 CKD patients and 67 healthy controls receiving a third dose of inactivated SARS-CoV-2 vaccine (Table S1) to evaluate the immunological enhancement in this population. This study was approved by the Peking University (27/45, 60.0%) followed by podocytopathy (5/45, 11.1%) and metabolic kidney disease (5/45, 11.1%). There were 18 patients taking immunosuppressants during the vaccination period with 17 (94.4%) receiving monotherapy. We tightly controlled age, female ratio, types of administered vaccines and sampling time across groups, except that the average age of diabetes patients is significantly older than CKD patients. None of these participants reported severe adverse effects after vaccination. Using neutralizing antibody titer of 2 as seroconversion cutoff, we found 84% (38 of 45) of CKD patients seropositive, which was lower than that in healthy controls (98%), hypertension patients (98%) and diabetes patients (95%). The median neutralizing antibody titers in CKD patients was 6.29 (IQR, 2.78-14.62), which was significantly lower than that in healthy controls [8.91 (IQR, 6.14-16.01), Our initial analysis showed that majority (84%) of CKD patients acquired detectable neutralizing antibody against SARS-CoV-2 without severe adverse effects, while the antibody titers were lower than controls. In contrast, we did not observe such difference in SARS-CoV-2-specific IgG or IgM. The deviance between neutralizing antibody and SARS-CoV-2-specific IgG responses in CKD patients indicates that neutralizing antibody rather than IgG might be the most important marker reflecting humoral immune response in CKD patients. Subgroup analyses showed that immunosuppressive therapies rather than eGFR levels or disease diagnosis impair SARS-CoV-2 vaccine-induced immunity. Our analysis in non-dialysis kidney disease patients receiving inactivated SARS-CoV-2 vaccine greatly supplemented previous studies on immunosuppressive therapies (7, 8) , dialysis (9) , and kidney transplantation (10) impaired mRNA vaccine responses. We found that taking immunosuppressants hampers neutralizing antibody response in CKD patients and sensitizes neutralizing antibody response to kidney function. Additionally, our data demonstrates that CKD patients, even for those on immunosuppression treatment, can benefit from a third vaccination boost by improving their humoral immunity. None declared. Review of Early Immune Response to SARS-CoV-2 Vaccination Among Patients With CKD Meta-analysis of immunologic response after COVID-19 mRNA vaccination in solid organ transplant recipients Impaired humoral immunity to SARS-CoV-2 BNT162b2 vaccine in kidney transplant recipients and dialysis patients Long-term efficacy and safety of SARS-CoV-2 vaccination in patients with chronic kidney disease, on dialysis or after kidney transplantation: a national prospective observational cohort study Loss of humoral response 3 months after SARS-CoV-2 vaccination in the CKD spectrum: the multicentric SENCOVAC study Antibody Response to mRNA Vaccines against SARS-CoV-2 with Chronic Kidney Disease, Hemodialysis, and after Kidney Transplantation Effect of Immunosuppression on the Immunogenicity of mRNA Vaccines to SARS-CoV-2: A Prospective Cohort Study Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort Neutralising antibodies after COVID-19 vaccination in UK haemodialysis patients Cellular and humoral response after MRNA-1273 SARS-CoV-2 vaccine in kidney transplant recipients The authors thank the study participants, and clinical staff and nurses who providing help for their participation and sampling.